NCT07749365招募中2 期
A Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Hypofractionated Radiotherapy Combined With Granulocyte-Macrophage Colony-Stimulating Factor, Pomalidomide and Glofitamab in Patients With Newly Diagnosed Primary Central Nervous System Diffuse Large B-Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- CR (Complete Response Rate)
研究概览
简要总结
This prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent must be obtained before any study-related procedures.
- •Age ≥18 years, regardless of sex, with an expected survival time >3 months.
- •Histologically confirmed diffuse large B-cell lymphoma (DLBCL).
- •Newly diagnosed patients with primary central nervous system diffuse large B-cell lymphoma (PCNSL).
- •No previous treatment with bispecific antibodies.
- •B-cell non-Hodgkin lymphoma with at least one measurable lesion according to RECIST 1.1 criteria, or detectable abnormal monoclonal B cells by cerebrospinal fluid (CSF) flow cytometry.
- •Adequate organ function meeting the following laboratory criteria:
- •Total bilirubin ≤1.5 × upper limit of normal (ULN);
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN;
- •Serum creatinine ≤1.5 × ULN and creatinine clearance ≥60 mL/min (calculated using the Cockcroft-Gault formula);
- •Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN.
- •Women of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first dose of study treatment (Cycle 1 Day 1). If urine pregnancy testing cannot confirm a negative result, a serum pregnancy test is required. Women of non-childbearing potential are defined as those who are postmenopausal for ≥1 year or have undergone surgical sterilization or hysterectomy.
- •All participants with reproductive potential (male or female) must use highly effective contraception with a failure rate <1% per year during treatment and for 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy).
排除标准
- •Loss of CD20 expression in B-cell non-Hodgkin lymphoma.
- •Active acute or chronic hepatitis B or hepatitis C infection, including:
- •HBV DNA >2,000 IU/mL or >10⁴ copies/mL without willingness to receive regular antiviral therapy;
- •HCV RNA >10³ copies/mL;
- •Concurrent positivity for HBsAg and anti-HCV antibody.
- •Receipt of anti-hematologic malignancy therapy within 2 weeks or within 5 pharmacokinetic half-lives before treatment initiation, whichever is longer.
- •Inadequate bone marrow reserve, defined as platelet count <30 ×10⁹/L or absolute neutrophil count <1.0 ×10⁹/L.
- •Clinically significant pulmonary diseases, including:
- •Chronic obstructive pulmonary disease (COPD) with FEV1 <50% of predicted value;
- •Moderate or severe persistent asthma within the past 2 years or uncontrolled asthma of any severity.
- •Uncontrolled hypertension despite optimal medical management (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg), history of hypertensive crisis, or hypertensive encephalopathy.
- •Symptomatic congestive heart failure (NYHA class II-IV), symptomatic or poorly controlled arrhythmias, congenital long QT syndrome, or corrected QT interval (QTc) >500 ms (Fridericia correction).
- •Receipt of hypofractionated radiotherapy within 4 weeks before the first treatment. Patients receiving radiotherapy >4 weeks before enrollment must have no ongoing radiation-related toxicities, no requirement for corticosteroids, and no evidence of radiation pneumonitis, hepatitis, enteritis, or other radiation-related complications.
- •Difficulty swallowing oral medications.
- •History or presence of pulmonary fibrosis, interstitial lung disease, pneumoconiosis, drug-induced pneumonitis, or severe pulmonary dysfunction.
- •HIV infection (positive HIV-1/2 antibody) or known syphilis infection.
- •Presence of unhealed wounds, fractures, gastric or duodenal ulcers, persistent positive fecal occult blood test, ulcerative colitis, or other conditions associated with risk of gastrointestinal bleeding or perforation as determined by the investigator.
- •Active or uncontrolled severe infection, including severe infection requiring hospitalization due to infection, bacteremia, or severe pneumonia within 4 weeks before the first dose.
- •Major surgery or significant traumatic injury within 4 weeks before the first dose.
- •Use of traditional Chinese medicine with antitumor indications within 2 weeks before the first dose.
- •Known hypersensitivity to any component of bispecific antibodies or GM-CSF preparations.
- •Receipt of treatment in another clinical trial within 4 weeks before the first dose.
- •Pregnant or breastfeeding women.
- •Active autoimmune disease or history of autoimmune disease, including but not limited to autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, and nephritis. Patients requiring medical intervention with bronchodilators for asthma are excluded. The following conditions are permitted: vitiligo, psoriasis, alopecia, or controlled type I diabetes not requiring systemic treatment, and hypothyroidism controlled with hormone replacement therapy.
- •Any other acute or chronic disease, psychiatric condition, or abnormal laboratory finding that may:
- •Increase the risk associated with study participation or administration of study treatment;
- •Interfere with interpretation of study results;
- •Render the patient unsuitable for participation according to the investigator's judgment.
研究组 & 干预措施
hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating
Experimental
After signing the informed consent, patients may receive pretreatment with dexamethasone (10 mg/day, maximum dose 30 mg) and/or pomalidomide 4 mg/day for up to 7 days. In Cycle 1, patients receive hypofractionated radiotherapy at 5 Gy per day for 3 consecutive days. One to two cycles of radiotherapy will be administered for a single target lesion, with the radiotherapy regimen determined by the investigator.
GM-CSF at 400 μg once daily is administered for 3 consecutive days starting on Day 1 after radiotherapy completion. Pomalidomide 4 mg once daily is given for 14 consecutive days starting on Day 1 after radiotherapy completion. If pomalidomide is used during pretreatment, the total duration of pomalidomide (pretreatment plus post-radiotherapy administration) shall not exceed 14 days. Dose escalation of glofitamab commences on Day 7 after radiotherapy completion.
Cycles 2 to 6 are administered on a 21-day cycle schedule. GM-CSF 400 μg once daily is given for 3 consecutive days start
干预措施: hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab (Drug)
结局指标
主要结局
CR (Complete Response Rate)
时间窗: Up to 12 months
The primary efficacy endpoint is the complete response (CR) rate, defined as the proportion of patients achieving complete response according to the Lugano response criteria.
次要结局
- ORR (Objective Response Rate)(Up to 12 months)
- Duration of Response (DoR)(Up to 12 months)
研究者
Zhijuan Lin
DR
The First Affiliated Hospital of Xiamen University
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaCervical CancerNCT07276360Uganda Cancer Institute278
尚未招募
2/3 期
A study to assess the response of Radiotherapy in Inoperable Breast Cancer Patients not responding to Preoperative Chemotherapy.CTRI/2026/01/100098Avni Saini30
尚未招募
2 期
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II TrialModerately Hypofractionated RadiotherapySerplulimabpMMR/MSSRectal CancerNCT07527520Fudan University165
尚未招募
不适用
Prospective Comparative Study of Hypofractionated Adjuvant Radiotherapy in 2 Virsus 3 Weeks in Breast CancerBreast CancerNCT07344597Salwa Shawky Bakeet Ali70
招募中
2 期
Hypofractionated Definitive Chemoradiotherapy for Oesophageal CancerNCT07632079Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)60